TW202328187A - 抗運鐵蛋白受體抗體及其用途 - Google Patents

抗運鐵蛋白受體抗體及其用途 Download PDF

Info

Publication number
TW202328187A
TW202328187A TW111132949A TW111132949A TW202328187A TW 202328187 A TW202328187 A TW 202328187A TW 111132949 A TW111132949 A TW 111132949A TW 111132949 A TW111132949 A TW 111132949A TW 202328187 A TW202328187 A TW 202328187A
Authority
TW
Taiwan
Prior art keywords
seq
amino acid
acid sequence
antibody
tfr1
Prior art date
Application number
TW111132949A
Other languages
English (en)
Chinese (zh)
Inventor
利多 伊辛 達琦立
班傑明 Ａ 史密斯
卡爾 Ｊ Ｍ 漢夫
芳 錢
Ｒ 伯瑞克 佩賓斯基
湯瑪士 Ｏ 卡麥隆
Original Assignee
美商百健Ｍａ公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商百健Ｍａ公司 filed Critical 美商百健Ｍａ公司
Publication of TW202328187A publication Critical patent/TW202328187A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW111132949A 2021-09-01 2022-08-31 抗運鐵蛋白受體抗體及其用途 TW202328187A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163239630P 2021-09-01 2021-09-01
US63/239,630 2021-09-01
US202263388088P 2022-07-11 2022-07-11
US63/388,088 2022-07-11

Publications (1)

Publication Number Publication Date
TW202328187A true TW202328187A (zh) 2023-07-16

Family

ID=83508506

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111132949A TW202328187A (zh) 2021-09-01 2022-08-31 抗運鐵蛋白受體抗體及其用途

Country Status (15)

Country Link
US (2) US11827702B2 (OSRAM)
EP (1) EP4396231A1 (OSRAM)
JP (1) JP2024534880A (OSRAM)
KR (1) KR20240107202A (OSRAM)
AU (1) AU2022340568A1 (OSRAM)
CA (1) CA3230796A1 (OSRAM)
CL (1) CL2024000642A1 (OSRAM)
CO (1) CO2024003577A2 (OSRAM)
CR (1) CR20240139A (OSRAM)
IL (1) IL311175A (OSRAM)
JO (1) JOP20240042A1 (OSRAM)
MX (1) MX2024002753A (OSRAM)
PE (1) PE20240895A1 (OSRAM)
TW (1) TW202328187A (OSRAM)
WO (1) WO2023034409A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120882749A (zh) * 2023-03-08 2025-10-31 渤健马萨诸塞州股份有限公司 抗转铁蛋白受体抗体及其用途
KR20260044219A (ko) 2023-07-21 2026-04-01 매로우 테라퓨틱스, 인크. 조혈 세포 표적화 접합체 및 관련 방법
CN116735864B (zh) * 2023-08-15 2023-11-10 迦进生物医药(上海)有限公司 评估TfR1抗体血液安全性的试剂盒
TW202517685A (zh) * 2023-10-26 2025-05-01 美商百健Ｍａ公司 抗運鐵蛋白受體抗體及其用途
CN121517563A (zh) * 2024-08-09 2026-02-13 东北制药集团股份有限公司 人源化的靶向TfR1的抗体及其应用
WO2026076250A1 (en) * 2024-10-03 2026-04-09 Genentech, Inc. Lipid nanoparticles for delivery to the cns from systemic administration

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004753A1 (en) 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
CA2081368A1 (en) 1990-03-27 1991-09-28 Ian S. Trowbridge Method for inhibiting cell growth and compositions useful therefor
US5648469A (en) 1992-04-20 1997-07-15 The Salk Institute For Biological Studies Monoclonal antibodies reactive with transferrin receptor cytoplasmic domain
WO2005094364A2 (en) 2004-03-31 2005-10-13 Chimeric Technologies, Inc. Iga antibody protein as a cytotoxic drug
CA2561830C (en) 2004-03-31 2013-05-21 Adnagen Ag Monoclonal antibodies with specificity for fetal erythroid cells
WO2005111082A1 (en) 2004-04-30 2005-11-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-tfr antibody.
AU2005252699B2 (en) 2004-06-07 2010-12-23 Macrogenics West, Inc. Transferrin receptor antibodies
CZ200755A3 (cs) 2004-07-26 2007-04-11 Biogen Idec Ma Inc. Peptidy protilátek anti-CD154
JP2008531060A (ja) 2005-03-04 2008-08-14 バイオジェン・アイデック・エムエイ・インコーポレイテッド 相補性決定残基の合理的改変を介して免疫グロブリン可変領域をヒト化する方法
US7736647B2 (en) 2005-06-15 2010-06-15 Monoclonal Antibodies Therapeutics Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
FR2953841B1 (fr) 2009-12-16 2011-12-30 Centre Nat Rech Scient Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer
FR2959416B1 (fr) 2010-05-03 2012-06-22 Monoclonal Antibodies Therapeutics Mat Biopharma Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament
WO2012075037A1 (en) 2010-11-30 2012-06-07 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
CN103534272B (zh) 2011-05-09 2016-05-11 株式会社英仙蛋白质科学 能够特异性识别转铁蛋白受体的抗体
TWI450727B (zh) 2011-12-29 2014-09-01 財團法人工業技術研究院 抗人類輸鐵蛋白受體的單域抗體與其應用
US20130177579A1 (en) 2012-01-06 2013-07-11 Bioalliance C.V. Anti-transferrin receptor antibodies and methods using same
RU2711552C2 (ru) 2012-08-29 2020-01-17 Ф. Хоффманн-Ля Рош Аг Шаттл для гематоэнцефалического барьера
CA2893794C (en) 2012-11-08 2021-11-09 University Of Miyazaki Antibody capable of specifically recognizing transferrin receptor
WO2014144060A1 (en) 2013-03-15 2014-09-18 Alper Biotech, Llc Monoclonal antibodies to transferrin and transferrin receptor antigens, and uses thereof
EA038367B1 (ru) 2013-05-20 2021-08-16 Дженентек, Инк. АНТИТЕЛА ПРОТИВ РЕЦЕПТОРА ТРАНСФЕРРИНА (TfR) И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ
US9499628B2 (en) 2013-06-14 2016-11-22 Children's Hospital Medical Center Method of boosting the immune response in neonates
EP3450557A1 (en) 2013-12-25 2019-03-06 JCR Pharmaceuticals Co., Ltd. Novel anti-transferrin receptor antibody that passes through blood-brain barrier
JP6557664B2 (ja) 2014-01-06 2019-08-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 一価の血液脳関門シャトルモジュール
JP6779876B2 (ja) 2014-11-19 2020-11-04 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及びその使用方法
IL310251A (en) 2015-05-04 2024-03-01 Cytomx Therapeutics Inc Anti-cd71 antibodies, activatable anti-cd71 antibodies, compositions comprising same and uses thereof
CR20210429A (es) 2015-06-24 2021-09-24 Hoffmann La Roche ANTICUERPOS ANTI-RECEPTOR DE TRANSFERRINA CON AFINIDAD DISEÑADA (Divisional 2017-0562)
KR20250073514A (ko) 2015-06-24 2025-05-27 제이씨알 파마 가부시키가이샤 혈액뇌관문을 통과하는 항인간 트랜스페린 수용체 항체
EP3325509B1 (en) 2015-07-22 2020-12-16 Inatherys Anti-tfr antibodies and their use in treating proliferative and inflammatory disorders
TWI819458B (zh) 2015-10-02 2023-10-21 瑞士商赫孚孟拉羅股份公司 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
KR102775461B1 (ko) 2016-04-01 2025-02-28 어비디티 바이오사이언시스 인크. 핵산-폴리펩타이드 조성물 및 이의 용도
US20190240346A1 (en) 2016-06-20 2019-08-08 Genahead Bio, Inc. Antibody-drug conjugate
US20190375819A1 (en) 2016-10-29 2019-12-12 Rhode Island Hospital Glycosylated transferrin receptor 1 tumor antigen
NZ752703A (en) 2016-12-26 2022-09-30 Japan Chem Res Novel anti-human transferrin receptor antibody capable of penetrating blood-brain barrier
CN110506054A (zh) 2017-02-17 2019-11-26 戴纳立制药公司 经工程改造的多肽
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
HUE063021T2 (hu) 2017-08-10 2023-12-28 Denali Therapeutics Inc Mesterségesen elõállított transzferrin receptor-kötõ polipeptidek
CN118638788A (zh) 2017-12-06 2024-09-13 艾维迪提生物科学公司 治疗肌萎缩和强直性肌营养不良的组合物和方法
SG11202006433PA (en) 2018-02-05 2020-08-28 Jcr Pharmaceuticals Co Ltd Method for delivering drug to muscle
US20220378934A1 (en) 2018-08-02 2022-12-01 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof in treating muscle atrophy
CA3108287A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
MX2021001282A (es) 2018-08-02 2021-07-15 Dyne Therapeutics Inc Complejos dirigidos al músculo y sus usos.
JP7611825B2 (ja) 2018-08-02 2025-01-10 ダイン セラピューティクス，インコーポレーテッド ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用
EA202190418A1 (ru) 2018-08-02 2021-06-23 Дайн Терапьютикс, Инк. Мышечно-специфические комлексы и их применение в лечении прогрессирующей оссифицирующей фибродисплазии
EP3829594A4 (en) 2018-08-02 2022-05-11 Dyne Therapeutics, Inc. MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
US20210322562A1 (en) 2018-08-02 2021-10-21 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating centronuclear myopathy
CA3108285A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating pompe disease
US20220193250A1 (en) 2018-08-02 2022-06-23 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US20210308274A1 (en) 2018-08-02 2021-10-07 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating friedreich's ataxia
WO2020104479A1 (en) 2018-11-20 2020-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
WO2021076856A1 (en) 2019-10-18 2021-04-22 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
CA3163608A1 (en) 2020-01-10 2021-07-15 Romesh R. Subramanian Muscle-targeting complexes and uses thereof
IL294479A (en) 2020-01-10 2022-09-01 Dyne Therapeutics Inc Muscle targeting complexes and their uses for the treatment of myotonic dystrophy
US12624120B2 (en) * 2020-01-31 2026-05-12 Dyne Therapeutics, Inc. Anti-transferrin receptor (TfR) antibody and uses thereof
WO2022020105A1 (en) 2020-07-23 2022-01-27 Dyne Therapeutics, Inc. Anti-transferrin receptor (tfr) antibody and uses thereof
CA3202832A1 (en) 2020-12-31 2022-07-07 Romesh R. Subramanian Muscle targeting complexes and uses thereof for treating myotonic dystrophy

Also Published As

Publication number Publication date
US20240158494A1 (en) 2024-05-16
PE20240895A1 (es) 2024-04-24
CL2024000642A1 (es) 2024-09-13
CO2024003577A2 (es) 2024-06-27
IL311175A (en) 2024-04-01
EP4396231A1 (en) 2024-07-10
US20230131379A1 (en) 2023-04-27
MX2024002753A (es) 2024-05-20
KR20240107202A (ko) 2024-07-08
JP2024534880A (ja) 2024-09-26
CR20240139A (es) 2024-06-14
US11827702B2 (en) 2023-11-28
AU2022340568A1 (en) 2024-03-28
WO2023034409A1 (en) 2023-03-09
CA3230796A1 (en) 2023-03-09
JOP20240042A1 (ar) 2024-02-29

Similar Documents

Publication Publication Date Title
US11827702B2 (en) Anti-transferrin receptor antibodies and uses thereof
EP2280732B1 (en) Antibodies to granulocyte-macrophage colony-stimulating factor
JP2023538945A (ja) 抗ｒｏｒ１抗体及び関連の二重特異性結合タンパク質
CA3053379A1 (en) Anti-tau antibodies and methods of use thereof
CA2977621C (en) Antibody binding to tfpi and composition comprising the same
CN118215682A (zh) 抗转铁蛋白受体抗体及其用途
CN106459216A (zh) 多特异性抗体构建体
US20130336984A1 (en) Antagonistic dr3 ligands
CN108712908A (zh) 自交联抗体
US20170281711A1 (en) Activin Type 2 Receptor Binding Proteins and Uses Thereof
CN115279787B (zh) 抗硬骨抑素构建体及其用途
WO2020132356A1 (en) Antigen binding formats for receptor complexes
TW202144431A (zh) 工程化抗her2雙特異性蛋白
IL281351B1 (en) Enhanced anti-flt3 antigen-binding proteins
JP2021119788A (ja) 多重特異的結合タンパク質
WO2019094576A1 (en) Bace-tau bispecific antibodies
WO2021026609A1 (en) Complement c2 binding proteins and uses thereof
CA3254085A1 (en) KLRB1 LIAISON AGENTS AND THEIR METHODS OF USE
US12630616B2 (en) Complement C2 binding proteins and uses thereof
CN118139882A (zh) 骨骼肌肉系统疾病的治疗
JP2024534824A (ja) 操作された抗ｈｅｒ２二重特異性タンパク質
HK40112185A (zh) 抗硬骨抑素构建体及其用途
HK40111822A (zh) 抗硬骨抑素构建体及其用途
HK40111824A (zh) 抗硬骨抑素构建体及其用途
HK40112195A (zh) 抗硬骨抑素构建体及其用途